# Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab

> **NCT00062894** · PHASE1,PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 12 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Iodine I 131 Tositumomab

## Key facts

- **NCT ID:** NCT00062894
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04
- **Primary completion:** —
- **Final completion:** 2007-04
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2007-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00062894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00062894, "Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00062894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*